The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Trabectedin (Yondelis) for Metastatic Liposarcoma or Leiomyosarcoma
(Notification to Implement issued as of August 22, 2016)
Vandetanib (Caprelsa) for Medullary Thyroid Cancer
(Open for Input on Submission until August 29, 2016)
Carfilzomib (Kyprolis) for Multiple Myeloma (relapsed/refractory)
(Pending Submission as of August 11, 2016)
Ibrutinib (Imbruvica) for Mantle Cell Lymphoma
(Notification to Implement Issued as of August 4, 2016)